fluorobenzenes has been researched along with Coronary Artery Disease in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (37.89) | 29.6817 |
| 2010's | 59 (62.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daida, H; Hirayama, A; Hiro, T; Kawashiri, MA; Matsuzaki, M; Saito, S; Sakamoto, T; Takayama, T; Yamagishi, M; Yamaguchi, T | 1 |
| Canziani, ME; Carvalho, AB; Christofalo, DM; Draibe, SA; Jancikic, AD; Lemos, MM; Sanches, FM; Watanabe, R | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; St John, J; Uno, K; Wolski, K | 1 |
| Fukuda, S; Jissho, S; Kono, Y; Kubo, T; Nakanishi, K; Otsuka, K; Shimada, K; Taguchi, H; Yoshikawa, J; Yoshiyama, M | 1 |
| Abaci, O; Coskun, U; Kilickesmez, KO; Kocas, C; Oktay, V; Yigit, Z; Yildiz, A; Yildiz, CE | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 4 |
| Itoh, T; Nakamura, M; Satoh, M; Tabuchi, T | 2 |
| de Graaf, MA; Jukema, JW | 1 |
| Takagi, H; Umemoto, T | 1 |
| Branny, M; Brůhová, H; Hájek, P; Matějovič, M; Studenčan, M; Tesař, D; Tomašov, P; Veselka, J; Zemánek, D | 1 |
| Krysiak, R; Okopien, B | 1 |
| Che, W; Liu, B; Wang, H; Yan, H; Zhu, W | 1 |
| Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C | 1 |
| Mintz, GS | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Tuzcu, EM; Uno, K; Wolski, K | 1 |
| Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T | 1 |
| Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 2 |
| Ikeda, T; Ikuta, S; Iwanaga, Y; Kobuke, K; Miyazaki, S; Ueno, M; Yamaji, K; Yamamoto, H; Yasuda, M | 1 |
| Uemura, S | 1 |
| Amemiya, K; Ando, K; Domei, T; Goya, M; Iwabuchi, M; Shirai, S; Yokoi, H | 1 |
| Hwang, E; Jang, JY; Kang, DH; Kim, DH; Song, JM; Sun, BJ | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Cho, L; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Stegman, B; Uno, K | 1 |
| Campos, CM; Garcia-Garcia, HM; Serruys, PW | 1 |
| Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A | 1 |
| Qu, Y; Xia, J; Xu, D; Yin, C | 1 |
| Colivicchi, F | 1 |
| Dohi, K; Fujimoto, N; Ito, M; Masuda, J; Miyahara, M; Nakamura, M; Nakata, T; Nishikawa, M; Nishimura, Y; Sasou, T; Sawai, T; Tanigawa, T; Yamada, T | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| D'iachkov, VA; Danilova, EA; Medvedeva, EA; Pikatova, EA; Seleznev, EI; Shchukin, IuV | 1 |
| Kaneda, H | 1 |
| Blumenthal, RS; Kapur, NK; Sutton, BS | 1 |
| Alipour, A; Castro Cabezas, M; Dallinga-Thie, GM; Plokker, HW; Sijmonsma, TP; van Oostrom, AJ; Verseyden, C | 1 |
| Scheen, AJ | 2 |
| Averna, M; Brudi, P; Farnier, M; Johnson-Levonas, AO; Massaad, R; Missault, L; Vandormael, K; Vaverkova, H; Viigimaa, M | 1 |
| Drexel, H; Rein, P; Saely, CH; Vonbank, A | 1 |
| Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J | 1 |
| Cain, VA; Libby, P; Mohanavelu, S; Nissen, SE; Raichlen, JS; Wiviott, SD | 1 |
| Belenkov, YN; Ezhov, MV; Gabrusenko, SA; Kuharchuk, VV; Masenko, VP; Semenova, AE; Sergienko, IV | 1 |
| Hong, MK; Kang, DH; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, JK | 1 |
| McDaniel, MC; Samady, H | 1 |
| Daida, H; Hirayama, A; Hiro, T; Matsuzaki, M; Saito, S; Takayama, T; Yamagishi, M; Yamaguchi, T | 2 |
| Adachi, T; Ohsuzu, F | 1 |
| Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M | 1 |
| Daitoku, K; Fukuda, I; Hanada, H; Higuma, T; Okumura, K; Osanai, T; Saito, S; Yokoyama, H | 1 |
| Grammer, TB; März, W | 1 |
| Ridker, PM | 1 |
| Molokwu, OC | 1 |
| Ahn, Y; Cho, JG; Choi, YH; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Ma, EH; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, NS; Youn, HJ | 1 |
| Drexel, H; Saely, CH; Vonbank, A | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Koshikawa, M; Koyama, J; Kumazaki, S; Miyashita, Y; Otagiri, K; Tomita, T; Tsutsui, H | 1 |
| Abd, TT; Bajpai, A; Dollar, A; Eapen, DJ; Goyal, A; Sperling, L | 1 |
| Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 1 |
| Endo, T; Fukui, K; Himeno, H; Iwahashi, N; Iwasawa, Y; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okada, K; Sawada, R; Shigemasa, T; Shimizu, M; Shimizu, T; Uchino, K; Umemura, S; Wada, A | 2 |
| Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; DeFilippis, AP; Lima, J; Nasir, K; O'Leary, DH; Rivera, JJ | 1 |
| Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Boersma, E; Garcia-Garcia, HM; Magro, M; Serruys, PW; Simsek, C; van Geuns, RJ | 1 |
| Liao, ZJ; Lin, ZP; Liu, Q; Shu, PC; Wang, XQ | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, M; Chapman, MJ; Erbel, RM; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Uno, K; Wolski, K | 1 |
| Garcia-Garcia, HM; Okamura, T; Serruys, PW; Shin, ES | 1 |
| Einecke, D | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Boersma, E; de Boer, S; Duckers, HJ; Garcia-Garcia, HM; Girasis, C; Lenzen, M; Magro, M; Raichlen, J; Regar, E; Serruys, PW; Simsek, C; van der Giessen, W; van der Steen, T; van Geuns, RJ; van Mieghem, N; Zijlstra, F | 1 |
| Nohara, R | 1 |
| Mao, X; Mao, Y; Meng, K; Tang, H; Wang, X; Yi, G; Zeng, Q; Zhong, Y | 1 |
| Caslake, M; Chapman, MJ; McTaggart, F; Packard, C | 1 |
| Stein, EA | 1 |
| Cabezas, MC; Jansen, EH; Plokker, HW; Rabelink, TJ; Stehouwer, CD; van Asbeck, BS; van Kessel, KP; van Oostrom, AJ | 1 |
| McKenney, JM | 1 |
| Ballantyne, CM; Cain, V; Crowe, T; Davignon, J; Erbel, R; Fruchart, JC; Goormastic, M; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Schoenhagen, P; Sipahi, I; Tardif, JC; Tuzcu, EM; Wolski, K | 1 |
| Jackson, G | 1 |
| Gratsianskiĭ, NA | 1 |
| Ayadhi, T; Böhm, M; Link, A; Nickenig, G | 1 |
| Nicholls, SJ; Nissen, SE; Sipahi, I; Tuzcu, EM | 1 |
| Daida, H; Hiro, T; Matsuzaki, M; Saito, S; Takayama, T; Yamagishi, M; Yamaguchi, T | 1 |
| Kapur, NK | 1 |
| Schuster, H | 1 |
| Bots, ML; Crouse, JR; Evans, GW; Grobbee, DE; O'Leary, DH; Palmer, MK; Raichlen, JS; Riley, WA | 1 |
| Famularo, G; Grieco, A; Miele, L; Minisola, G | 1 |
| Dedhia, V; Munsi, SC | 1 |
| Ballantyne, CM; Brener, SJ; Cain, VA; Erbel, R; Nicholls, SJ; Nissen, SE; Raichlen, JS; Tardif, JC | 1 |
| Olsson, AG | 1 |
9 review(s) available for fluorobenzenes and Coronary Artery Disease
| Article | Year |
|---|---|
A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles.
Topics: Apolipoproteins; Atorvastatin; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
[C-reactive protein and coronary heart disease: quo vadis?].
Topics: Alleles; Apolipoproteins E; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Genetic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2009 |
The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial.
Topics: Biomarkers; C-Reactive Protein; Coronary Artery Disease; Evidence-Based Medicine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Predictive Value of Tests; Pyrimidines; Radiography; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Survival Analysis; Treatment Outcome | 2011 |
[COSMOS (coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects) trial].
Topics: Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
New dimension of statin action on ApoB atherogenicity.
Topics: Animals; Apolipoproteins B; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Pyrimidines; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides; Treatment Outcome | 2003 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Coronary atherosclerosis can regress with very intensive statin therapy.
Topics: Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2006 |
Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.
Topics: Adolescent; Adult; Age Factors; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Male; Middle Aged; Primary Prevention; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Analysis | 2007 |
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation Mediators; Male; Maximum Tolerated Dose; Program Evaluation; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides | 2007 |
46 trial(s) available for fluorobenzenes and Coronary Artery Disease
| Article | Year |
|---|---|
Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study.
Topics: Adult; Aged; Analysis of Variance; Calcinosis; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Polyamines; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sevelamer; Sulfonamides; Tomography, X-Ray Computed | 2013 |
Factors underlying regression of coronary atheroma with potent statin therapy.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
Topics: Aged; Atorvastatin; Carrier Proteins; Case-Control Studies; Cell Line, Tumor; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Interleukin-18; Interleukin-1beta; Lipids; Male; Middle Aged; NLR Family, Pyrin Domain-Containing 3 Protein; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Period; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Troponin I | 2014 |
Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; rho-Associated Kinases; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Vascular Stiffness | 2013 |
Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.
Topics: Atorvastatin; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2014 |
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Difference in statin effects on neointimal coverage after implantation of drug-eluting stents.
Topics: Aged; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2014 |
Suppressive effects of standard-dose rosuvastatin therapy on the progression of coronary atherosclerosis in Japanese patients: the APOLLO study.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Artery Disease; Disease Progression; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Stents; Sulfonamides | 2014 |
Effect of rosuvastatin on coronary flow reserve in patients with systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Coronary Artery Disease; Coronary Circulation; Dose-Response Relationship, Drug; Echocardiography, Doppler; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery.
Topics: Aged; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Preoperative Care; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2015 |
Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
[JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2008 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Topics: Adult; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2009 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2009 |
Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
Topics: Aged; Cholesterol, VLDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides | 2009 |
Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis.
Topics: Aged; Calcinosis; Coronary Angiography; Coronary Artery Disease; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Necrosis; Predictive Value of Tests; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Topics: Aged; Asian People; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2009 |
Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients? Rationale and design of the JART study.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Japan; Male; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Tunica Intima; Tunica Media; Young Adult | 2010 |
Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease.
Topics: Adiponectin; Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heart Valve Diseases; Humans; Interleukin-6; Intra-Abdominal Fat; Male; Middle Aged; Oxidative Stress; Pravastatin; Protein Carbonylation; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Tumor Necrosis Factor-alpha | 2011 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Echocardiography; Exercise; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Smoking; Sulfonamides; Ubiquinone | 2011 |
Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal.
Topics: Aged; Atorvastatin; Cell Line; Coronary Artery Disease; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Toll-Like Receptor 4 | 2012 |
[Rosuvastatin improves myocardial function and arteriosclerosis plaque in patients with ST-segment elevation after acute myocardial infarction and percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Electrocardiography; Female; Fluorobenzenes; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Effect of two intensive statin regimens on progression of coronary disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2011 |
MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression.
Topics: Aged; Atorvastatin; Cell Count; Cell Movement; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Longevity; Male; MicroRNAs; Oxidative Stress; Pyrimidines; Pyrroles; RNA, Messenger; Rosuvastatin Calcium; Sirtuin 1; Sulfonamides; Transfection | 2012 |
Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
Topics: Atorvastatin; Coronary Angiography; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Republic of Korea; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
[COSMOS (coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects) trial].
Topics: Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Exercise; Fluorobenzenes; Heptanoic Acids; Humans; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness | 2012 |
High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese
Topics: Aged; Asian People; Biomarkers; Chi-Square Distribution; Coronary Artery Disease; Coronary Vessels; Female; Fluorobenzenes; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Linear Models; Lipids; Male; Middle Aged; Multivariate Analysis; Plaque, Atherosclerotic; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.
Topics: Adult; Antigens, CD; CD11a Antigen; CD11b Antigen; Cell Adhesion Molecules; Chemotaxis, Leukocyte; Coronary Artery Disease; Dietary Fats; Erythrocyte Count; Fluorobenzenes; GPI-Linked Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interleukin-8; L-Selectin; Leukocytes; Male; Middle Aged; Neutrophils; Oxidative Stress; Platelet Count; Postprandial Period; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Cell Adhesion Molecule-1 | 2006 |
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2006 |
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Topics: Aged; C-Reactive Protein; Coronary Artery Disease; Cytokines; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lipids; Male; Middle Aged; Monocytes; Myocardial Ischemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; T-Lymphocytes | 2006 |
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultras
Topics: Adult; Aged; Atherosclerosis; Coronary Artery Disease; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2007 |
Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study.
Topics: Age Factors; Aged; Body Mass Index; Carotid Artery, Common; Carotid Stenosis; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Humans; Male; Middle Aged; Multivariate Analysis; Probability; Prognosis; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Severity of Illness Index; Sex Factors; Sulfonamides; Survival Analysis; Tunica Intima; Tunica Media; United States | 2007 |
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.
Topics: Aged; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Female; Fluorobenzenes; Humans; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
A new statin: a new standard.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2001 |
41 other study(ies) available for fluorobenzenes and Coronary Artery Disease
| Article | Year |
|---|---|
Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japane
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2013 |
Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study.
Topics: Aged; Aged, 80 and over; Brachial Artery; Coronary Artery Disease; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Manometry; Microvessels; Middle Aged; Pyrimidines; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Comparison of rosuvastatin versus atorvastatin for preventing postoperative atrial fibrillation.
Topics: Atorvastatin; Atrial Fibrillation; Comorbidity; Coronary Artery Bypass; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Premedication; Prevalence; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
High coronary plaque load: a heavy burden.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
The effect of aggressive rosuvastatin treatment on steroid hormone production in men with coronary artery disease.
Topics: Adult; Aged; Blood Glucose; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Fluorobenzenes; Gonadal Steroid Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients.
Topics: Adiponectin; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Combined Modality Therapy; Coronary Artery Disease; Exercise Therapy; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Molecular Weight; Multivariate Analysis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statins and prevention of stent-related late adverse events.
Topics: Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neointima; Percutaneous Coronary Intervention; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
Women are from SATURN and men are from an ASTEROID: deciphering the REVERSAL of coronary atheroma.
Topics: Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Sulfonamides; Ultrasonography | 2014 |
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statin reloading before noncardiac surgery: a simple, safe and effective approach for reducing the risk of perioperative myocardial infarction.
Topics: Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Postoperative Complications; Pyrimidines; Sulfonamides | 2015 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
[Molecular mechanisms of effects of rosuvastatin on systemic oxidative stress and endogenous inflammation in patients with atherosclerosis].
Topics: Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Letter by Kaneda regarding article, "Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden".
Topics: Adult; Aged; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Letter by Sutton et al regarding article, "Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burde
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Comparison of different methods to investigate postprandial lipaemia.
Topics: Area Under Curve; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Postprandial Period; Pyrimidines; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective.
Topics: Aged; Atherosclerosis; Biomarkers; C-Reactive Protein; Cohort Studies; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides | 2010 |
The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients.
Topics: Angioplasty, Balloon, Coronary; C-Reactive Protein; Coronary Artery Disease; Female; Fibroblast Growth Factor 2; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Revascularization; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2009 |
Can statins alter coronary plaque composition assessed by radiofrequency backscatter intravascular ultrasound?
Topics: Calcinosis; Coronary Artery Disease; Fatty Acids, Monounsaturated; Fibrosis; Fluorobenzenes; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Necrosis; Observer Variation; Predictive Value of Tests; Pyrimidines; Radiography; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Cosmic effect of rosuvastatin in COSMOS.
Topics: Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Statin therapy for elevated hsCRP: what are the public health implications?
Topics: Anticholesteremic Agents; C-Reactive Protein; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Public Health; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States | 2010 |
Statin therapy for elevated hsCRP: more evidence is needed.
Topics: Anticholesteremic Agents; C-Reactive Protein; Coronary Artery Disease; Evidence-Based Medicine; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States | 2010 |
Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/day.
Topics: Angina Pectoris; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Ultrasonography, Interventional | 2010 |
HDL cholesterol and residual risk of first cardiovascular events.
Topics: Cholesterol, HDL; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2010 |
Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study).
Topics: Acute Coronary Syndrome; Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Calcium; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Tomography, X-Ray Computed | 2011 |
Change in near-infrared spectroscopy of a coronary artery after 1-year treatment with high dose rosuvastatin.
Topics: Adult; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Rosuvastatin Calcium; Spectroscopy, Near-Infrared; Sulfonamides; Treatment Outcome | 2012 |
Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study.
Topics: Aged; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Fibrosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Necrosis; Odds Ratio; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Calcification | 2012 |
[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2011 |
The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3).
Topics: Biomarkers; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Research Design; Rosuvastatin Calcium; Spectroscopy, Near-Infrared; Sulfonamides; Ultrasonography, Interventional | 2012 |
Total cholesterol content of erythrocyte membranes is associated with the severity of coronary artery disease and the therapeutic effect of rosuvastatin.
Topics: Aged; Case-Control Studies; Cholesterol; Coronary Artery Disease; Erythrocyte Membrane; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides | 2012 |
Introduction: rosuvastatin--an efficacy assessment based on pooled trial data.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
[New statin introduction. With more power against hypercholesterolemia].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2002 |
ASTEROID--when spinning a star leads to a collision with reality.
Topics: Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Marketing; Mass Media; Pyrimidines; Research Design; Rosuvastatin Calcium; Sulfonamides | 2006 |
[Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg].
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2006 |
[Pronounced lowering of low density cholesterol combined with elevation of high density cholesterol was associated with reduction of coronary atheroma. Results of ASTEROID trial].
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Congresses as Topic; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Med could reverse arterial blockages.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Liver toxicity of rosuvastatin therapy.
Topics: Chemical and Drug Induced Liver Injury; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
Myopathy caused by a combination rosuvastatin and fenofibrate.
Topics: Aged; Coronary Artery Disease; Drug Interactions; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Muscular Diseases; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides | 2007 |
Will drugs someday reverse CAD? Three recent advances bring the possibility closer to reality.
Topics: Apolipoprotein A-I; Coronary Artery Disease; Fluorobenzenes; Humans; Hypertension; Hypolipidemic Agents; Pyrimidines; Remission Induction; Rosuvastatin Calcium; Sulfonamides | 2007 |